| Bioactivity | TAT-PAK18 inhibitory peptide is a membrane-permeable PAK inhibitory peptide. TAT-PAK18 inhibitory peptide reduces F-actin clusters and occludes the effect of Shank3 knockdown[1]. |
| Name | TAT-PAK18 inhibitory peptide |
| Sequence | Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Gly-Pro-Pro-Val-Ile-Ala-Pro-Arg-Pro-Glu-His-Thr-Lys-Ser-Val-Tyr-Thr-Arg-Ser |
| Shortening | RKKRRQRRRGPPVIAPRPEHTKSVYTRS |
| Formula | C146H254N58O37 |
| Molar Mass | 3413.95 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lara J Duffney, et al. Shank3 deficiency induces NMDA receptor hypofunction via an actin-dependent mechanism. J Neurosci. 2013 Oct 2;33(40):15767-78. |
TAT-PAK18 inhibitory peptide
CAS: F: C146H254N58O37 W: 3413.95
TAT-PAK18 inhibitory peptide is a membrane-permeable PAK inhibitory peptide. TAT-PAK18 inhibitory peptide reduces F-acti
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.